The Evolution of CRISPR: Companies Targeting the Epigenome for Disease Therapy
As CRISPR technology advances, companies are now exploring epigenome modifications, opening new avenues for treating various diseases.
Editorial Staff
1 min read
Updated 5 days ago
CRISPR technology is undergoing significant evolution, moving beyond traditional gene editing techniques.
A number of companies are now focusing on modifying the epigenome, which could have implications for a wide range of diseases.
This shift in focus highlights the potential of CRISPR to not only edit genes but also to influence gene expression through epigenetic changes.